Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use

Abstract

The antiandrogenic therapy (ADT) for prostate cancer represents an additional risk factor for the development of osteoporosis and fragility fractures. Still, bone health of patients on ADT is often not evaluated. After literature research we found that simple preventive measures can prevent bone loss in these patients, resulting in more cost-effective solutions to the public health system and family when compared to the treatment of fractures.

Prostate Cancer in Elderly Men

“…Therapy is associated with several well-documented QOL-affecting toxicities including hot flashes, emotional lability, headaches, and nausea and vomiting. 51 In addition, ADT is associated with increased risks for toxicities that are particularly dangerous in elderly patients. For example, men on ADT are at an increased risk for loss of bone mineral density and subsequent fracture.…”